Abivax Presents New Findings on Obefazimod at UEG 2025

Abivax has announced the acceptance of an additional late-breaking abstract for its lead drug candidate, obefazimod, in the treatment of ulcerative colitis. The findings, from their ABTECT Phase 3 induction trials, will be presented at the 2025 United European Gastroenterology (UEG) Meeting in Berlin. This presentation highlights significant results on the efficacy and safety of obefazimod during the 8-week trials, offering potential as a novel oral treatment for patients with moderately to severely active ulcerative colitis.

Dr. Fabio Cataldi, Abivax’s Chief Medical Officer, emphasized the statistical and clinical importance of these results in providing new treatment options for patients in need of therapeutic alternatives. Presentations by Dr. Bruce Sands and Dr. Silvio Danese will further explore the drug's effectiveness, including its impact on patients who had inadequate responses to previous therapies.